@Article{Lewis2015,
journal="Journal of Contemporary Brachytherapy",
issn="1689-832X",
volume="7",
number="3",
year="2015",
title="Case reports
High-dose-rate brachytherapy – a novel treatment approach for primary clear cell adenocarcinoma of male urethra",
abstract=" The incidence of male urethral cancer is rare with age preponderance of 50 to 60 years. The standard management approach is surgery. Here, we present a novel treatment approach for male urethral cancer. Thirty-six year old male, case of primary clear cell adenocarcinoma of urethra who refused surgery, underwent cystoscopic assisted intraluminal HDR brachytherapy. Patient received a dose of 36 Gy in 9 fractions (4 Gy per fraction) followed by a boost of 24 Gy in 6 fractions. At 11 months post treatment, disease is well controlled with no post treatment toxicity so far. Intraluminal brachytherapy seems to be an effective novel treatment for male urethral cancer.",
author="Lewis, Shirley
and Pal, Mahendra
and Bakshi, Ganesh
and Ghadi, Yogesh G.
and Menon, Santosh
and Murthy, Vedang
and Mahantshetty, Umesh",
pages="248--251",
doi="10.5114/jcb.2015.52316",
url="http://dx.doi.org/10.5114/jcb.2015.52316"
}